Paxlovid works by blocking an enzyme the COVID-19 virus needs to copy itself inside your cells. It’s an antiviral pill taken at home for five days, and in clinical trials it reduced the risk of severe illness by up to 89% in high-risk, unvaccinated patients. Even in the real world, among people with prior vaccination or infection, it cut hospitalization rates by about 51%. The key is starting it early: within five days of your first symptoms.
How It Stops the Virus From Replicating
SARS-CoV-2, the virus behind COVID-19, hijacks your cells to produce long chains of proteins. Those protein chains need to be cut into smaller, functional pieces before the virus can assemble new copies of itself. The enzyme responsible for making those cuts is called the main protease, and it’s essential to the virus’s life cycle.
Paxlovid’s active ingredient, nirmatrelvir, fits into the active site of that protease and locks it in place. With the enzyme blocked, the virus can’t process its proteins, and replication stalls. Think of it like jamming a pair of scissors so they can’t open: the raw material is there, but nothing useful gets made. Because this enzyme is specific to the virus and not found in human cells, the drug targets the infection without broadly disrupting your body’s normal processes.
Why It Contains Two Pills
Each dose of Paxlovid is actually two separate medications packaged together. Nirmatrelvir does the antiviral work, while a second pill, ritonavir, acts as a booster. Your liver would normally break down nirmatrelvir quickly, clearing it from your bloodstream before it could do much good. Ritonavir slows that breakdown by blocking the liver enzyme responsible for metabolizing nirmatrelvir, keeping blood levels high enough to suppress the virus.
Ritonavir itself has no meaningful activity against COVID-19. Its entire role is pharmacological: without it, nirmatrelvir levels drop too low to work. Skipping the ritonavir or taking it inconsistently undermines the entire treatment. This is also why Paxlovid interacts with a long list of other medications. Ritonavir affects the same liver pathway that processes many common drugs, including certain cholesterol medications, blood thinners, heart rhythm drugs, and sedatives. Your prescriber will review your medication list carefully before writing the prescription, and you may need to pause or adjust certain drugs for the five-day course.
Who Qualifies for Treatment
Paxlovid is intended for people with mild to moderate COVID-19 who are at higher risk of becoming seriously ill. You don’t need to be hospitalized to qualify; in fact, it’s meant to keep you out of the hospital. Eligibility starts at age 12 (as long as you weigh at least 88 pounds), though most prescriptions go to adults.
Risk factors that typically make someone a candidate include diabetes, heart disease, obesity, chronic lung conditions like asthma or COPD, chronic kidney disease, active cancer, and immunosuppressive conditions or treatments. Adults 60 and older were eligible in clinical trials regardless of other conditions. Your doctor evaluates your individual medical history to determine whether the benefit outweighs the risks.
There are a few hard cutoffs. People with severe kidney impairment or severe liver disease should not take it. Those with moderate kidney impairment get a reduced dose: one nirmatrelvir tablet instead of two per dose, while the ritonavir stays the same.
When Timing Matters Most
Paxlovid must be started within five days of symptom onset. The sooner the better. Antivirals are most effective when viral replication is still ramping up. By the time someone is sick enough to need oxygen or hospital care, the damage is being driven more by the body’s inflammatory response than by the virus itself, and an antiviral has less to offer.
The standard course is five days, with doses taken twice a day (morning and evening). That’s a total of 30 nirmatrelvir pills and 10 ritonavir pills for someone with normal kidney function. If you test positive and have risk factors, the practical move is to contact a healthcare provider quickly rather than waiting to see if symptoms worsen.
How Well It Works in Practice
The landmark trial, called EPIC-HR, enrolled unvaccinated adults with at least one risk factor during the pre-Omicron period. In that group, Paxlovid reduced the combined risk of hospitalization or death by 89% compared to placebo. That was a striking number, but it reflected a specific population at a specific moment in the pandemic.
Real-world data from the CDC, collected between April and September 2022 during Omicron-dominant waves, found a 51% lower hospitalization rate among adults prescribed Paxlovid within five days of diagnosis. This included people who had been vaccinated or previously infected. The smaller effect size makes sense: baseline risk is lower when people have some existing immunity, so there’s less room for the drug to make a dramatic difference. Still, cutting hospitalization risk roughly in half is clinically meaningful, especially for older adults and those with multiple health conditions.
Common Side Effects
The most talked-about side effect is a metallic or bitter taste in the mouth, sometimes called “Paxlovid mouth.” It occurs in roughly 1% to 10% of people who take the drug. Some describe it as a persistent sour or metallic flavor that lingers between doses. It’s unpleasant but harmless and goes away once the course is finished.
Diarrhea, vomiting, and headache fall in the same frequency range. For most people, side effects are mild enough to tolerate for five days, especially weighed against the risk of a severe COVID-19 outcome. Serious allergic reactions are rare but possible, particularly in anyone with a known sensitivity to the drug’s components.
What About Rebound?
Some people feel better after finishing Paxlovid, then notice symptoms returning a few days later. This phenomenon, often called COVID rebound, got a lot of attention in 2022 and 2023. The concern was that the drug was suppressing the virus temporarily without fully clearing it.
Data from randomized trials tells a more nuanced story. Viral RNA rebound (detectable virus levels rising again after dropping) occurred in about 6% to 8% of Paxlovid recipients, compared to roughly 6% to 7% of people who took a placebo. The difference between the two groups was not statistically significant once the analysis accounted for people who had already responded to treatment by day five. In other words, rebound appears to be a feature of COVID-19 itself, not something unique to the drug. Some people’s immune systems simply take longer to fully clear the virus, regardless of treatment.
If rebound does occur, it’s typically mild and short-lived. The CDC has noted that most rebound cases resolve without additional treatment, though you may want to resume isolation precautions if symptoms return.